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DOI 10.1016/j.ccr.2010.11.013SUMMARYChromosome band 9p24 is frequently amplified in primarymediastinal B cell lymphoma (PMBL) and Hodgkin
lymphoma (HL). To identify oncogenes in this amplicon, we screened an RNA interference library targeting
amplicon genes and thereby identified JAK2 and the histone demethylase JMJD2C as essential genes in
these lymphomas. Inhibition of JAK2 and JMJD2C cooperated in killing these lymphomas by decreasing
tyrosine 41 phosphorylation and increasing lysine 9 trimethylation of histone H3, promoting heterochromatin
formation. MYC, a major target of JAK2-mediated histone phosphorylation, was silenced after JAK2 and
JMJD2C inhibition, with a corresponding increase in repressive chromatin. Hence, JAK2 and JMJD2C coop-
eratively remodel the PMBL and HL epigenome, offering amechanistic rationale for the development of JAK2
and JMJD2C inhibitors in these diseases.Significance
We show that the selective advantage of an amplicon for a malignant clone can be due to the cooperative oncogenic effects
of multiple genes within the amplicon. Two genes in the 9p24 amplicon of PMBL and HL, JAK2 and JMJD2C, cooperate to
modify the epigenome of these lymphomas, thereby promoting proliferation and survival. JAK2 signaling, fostered by an
autocrine IL-13 loop and the 9p24 amplicon, appears to be a pervasive feature among PMBL tumors. JAK2 inhibitors
emerge from this work as promising therapeutic agents that may have activity against a majority of PMBL and HL tumors.
JMJD2C inhibitors should also be developed because they might synergize with JAK2 inhibitors in the treatment of these
lymphomas.
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Cooperative Epigenetic Changes by OncogenesINTRODUCTION
Primary mediastinal B cell lymphoma (PMBL), a subtype of
diffuse large B cell lymphoma (DLBCL), shares clinical, biological
and genetic featureswith Hodgkin lymphoma (HL). PMBLandHL
usually occur in young patients, with most PMBLs and >50% of
HLs involving themediastinumat presentation. Despite profound
histological differences, the malignant cells of PMBL and HL
share a characteristic molecular signature, as revealed by gene
expression profiling (Rosenwald et al., 2003; Savage et al.,
2003). In addition, PMBL and HL share oncogenic mechanisms,
including activation of the NF-kB pathway (Lam et al., 2005;
Rosenwald et al., 2003; Savage et al., 2003). A recurrent genomic
copy number gain in these lymphomas involves a region on chro-
mosomeband9p24,whichoccurs in35%–45%ofPMBLcases
(Joos et al., 1996; Lenz et al., 2008;Meier et al., 2009; Rosenwald
et al., 2003) and33%of HL cases (Joos et al., 2000, 2003). One
gene in this interval is JAK2, which encodes a tyrosine kinase that
mediates signaling downstream of several cytokine receptors
(Bentz et al., 2001; Joos et al., 2003, 2000; Meier et al., 2009;
Rosenwald et al., 2003). Recurrent deletion of SOCS1, an inhib-
itor of JAK signaling, in PMBL and HL supports a pathogenetic
role for JAK2 in these lymphomas (Melzner et al., 2005; Mestre
et al., 2005; Mottok et al., 2009; Weniger et al., 2006). The cyto-
kine IL-13 has been proposed as an autocrine stimulus to JAK
signaling inHL (Skinnider et al., 2001, 2002), but the stimulus acti-
vating this pathway in PMBL has not been elucidated (Guiter
et al., 2004).
JAK kinases phosphorylate STAT transcription factors,
causing their relocation to the nucleus where they activate target
genes bearing STAT binding motifs (Ghoreschi et al., 2009). An
additional role for JAK signaling in reprogramming chromatin
has been revealed by genetic studies in Drosophila (Shi et al.,
2006, 2008) and by analysis of histone modifications in mamma-
lian cells (Dawson et al., 2009). Signaling by the Drosophila JAK
homolog Hopscotch causes a global decrease in histone H3
lysine 9 methylation and heterochromatin formation (Shi et al.,
2006). In human leukemia cells, nuclear JAK2 directly phosphor-
ylates the histone H3 tail on tyrosine 41, thereby blocking recruit-
ment of the heterochromatin protein HP1a (Dawson et al., 2009).
The starting point for the present study was the realization that
the recurrent 9p24 amplicon in PMBL and HL does not just
involve JAK2 but includes several other genes in the vicinity
(Rosenwald et al., 2003). The PDCD1LG2 gene in this interval
encodes the negative regulator of T cell activation PD-L2, which
blocks signaling from the T cell receptor by engaging the
receptor PD-1. Inasmuch as PMBL and HL often originate in
the thymus amidst a sea of T cells, overexpression of PD-L2
could plausibly contribute to these malignancies by interdicting
immune surveillance.
A putative oncogene in this amplicon is JMJD2C, which
encodes a demethylase for trimethylated lysine 9 of histone H3
(H3K9me3) as well as trimethylated lysine 36 of histone H3
(Cloos et al., 2006; Loh et al., 2007; Whetstine et al., 2006; Wiss-
mann et al., 2007). JMJD2C is amplified and overexpressed in
esophageal squamous carcinoma, breast cancer, metastatic
lung sarcomatoid carcinoma, and desmoplastic medulloblas-
tomas (Cloos et al., 2006; Ehrbrecht et al., 2006; Italiano et al.,
2006; Liu et al., 2009; Yang et al., 2000) and is involved inCana rare translocation in mucosa-associated lymphoid tissue
lymphoma (Vinatzer et al., 2008), supporting its oncogenic
potential. Moreover, knockdown of JMJD2C in breast, prostate,
and esophageal cancer cell lines suppresses their proliferation
(Cloos et al., 2006; Liu et al., 2009; Wissmann et al., 2007). The
mechanism by which JMJD2C is oncogenic is unknown,
although it could demethylate chromatin surrounding key onco-
genes, thereby activating their transcription.
In the present study, we took an unbiased approach using
RNA interference genetic screening to discover the functionally
critical genes in the 9p24 amplicon in PMBL and HL, and inves-
tigated whether amplicon genes cooperate to sustain the prolif-
eration and survival of these lymphomas.
RESULTS
Functional Genomics of the 9p24 Amplicon
To explore the extent of the chromosome 9p24 amplicon in
PMBL and HL, we analyzed array comparative genomic
hybridization (aCGH) data from PMBL patient biopsies (n = 31),
PMBL cell lines (n = 2), and HL cell lines (n = 3) (Figure 1A).
Gain and/or amplification of sequences on chromosome band
9p24 was detected in 45% of PMBL biopsies but less frequently
in the ABC DLBCL subtype (11%) and the GCB DLBCL subtype
(7%) (Lenz et al., 2008). Within an 3.5 megabase minimal
common region of copy number gain, 10 genes were upregu-
lated in expression in association with this amplicon (Figure 1B).
Because we observed no case that only amplified JAK2, we
hypothesized that this region might harbor several oncogenes
that confer a selective advantage on PMBL and HL cells.
To identify the genes in the 9p24 amplicon that are required for
PMBL and HL cell proliferation and survival, we performed
a genetic screen utilizing a library of small hairpin RNAs (shRNAs)
that mediate RNA interference (Figure 2A). Using a retroviral
vector for doxycycline-inducible shRNA expression (Ngo et al.,
2006), we created an shRNA library targeting 21 genes in the
9p24 amplicon and, as positive controls, genes encoding pro-
teasome and ribosome subunits, which are essential in all cell
types (Figure 1B; see also Table S1 available online).
We screened this library in a pooled fashion, searching for
shRNA vectors that decreased tumor cell proliferation and/or
survival over 21 days in culture in shRNA-induced cells relative
to uninduced cells (Ngo et al., 2006). We tested two PMBL and
three HL lines with the 9p24 amplicon as well as two ABCDLBCL
and two GCB DLBCL lines without the amplicon. As expected,
each of the control shRNAs targeting proteasome and ribosome
subunits was similarly toxic to all lines (Figure 2A, bottom panel).
To identify essential amplicon genes, we focused on shRNAs
that were toxic for PMBL and HL lines but not for control DLBCL
lines and we required that at least two distinct shRNAs targeting
the same gene had the same toxicity spectrum. By these criteria,
we identified three candidate genes whose knockdown was
toxic for PMBL and HL cells: JAK2, JMJD2C, and RANBP6, en-
coding a paralogue of RANBP1 with no known function (Fig-
ure 2A). shRNAs targeting these genes were strongly toxic for
two PMBL lines and one HL line with the 9p24 amplicon, but
not for two other HL lines or for the ABC and GCB DLBCL lines.
We confirmed that these shRNAs decreased expression of their
targets as expected (Figures S1A–S1C). The specificity of thecer Cell 18, 590–605, December 14, 2010 ª2010 Elsevier Inc. 591
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Figure 1. Chromosome 9p24 Amplification
(A) Array CGH data showing segments of chromosome
arm 9p with copy number gains in 18 out of 31 PMBL
biopsy samples and in PMBL and HL lines. The box shows
the locations of genes in the 3.5 Mb minimal region of
copy number amplification. The 10 genes labeled in red
were overexpressed in PMBL cases with the amplicon.
(B) Relative expression of 9p24 amplicon genes in cases
with and without the amplicon. Shown is the log2-fold
overexpression associated with the amplicon along with
the t test p-value for significance. See also Figure S2.
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Cooperative Epigenetic Changes by OncogenesshRNAs targeting JAK2, JMJD2C, or RANBP6 was further
demonstrated by the ability of their corresponding cDNAs to
rescue PMBL cells from their toxicity (Figure S1D).
JAK2, JMJD2C, and RANBP6 were each strong candidate
oncogenes because they were included in the minimal region
of gain/amplification in PMBL (Figure 1A) and because their
mRNA levels were correlated with DNA copy number increases
(Figure 1B; see also Figure S2). To validate the RNAi screening
results, we cloned shRNAs from the library into a retroviral vector
that coexpresses green fluorescent protein (GFP), allowing us to
gauge the toxicity of an shRNA by the percentage of GFP+ cells
over time (Figure 2B). For JAK2, JMJD2C, and RANBP6, two592 Cancer Cell 18, 590–605, December 14, 2010 ª2010 Elsevier Inc.different shRNAs displayed a strong time-
dependent toxicity for the two PMBL lines and
the L1236 HL line, in accord with the RNAi
screening, but had no effect on a variety of
ABC and GCB DLBCL lines (Figure 2B). In addi-
tion, these shRNAs were toxic for another HL
line with the 9p24 amplicon, U-H01 (Mader
et al., 2007), but had little if any toxicity to the
L540, KM-H2, and L428 HL lines, despite the
fact that they also bear this amplicon (Figure 1A)
(Joos et al., 2003). In the case of L540 and
KM-H2, the ineffectiveness of these individual
shRNAs can be traced to functional redundancy
of cancer amplicon genes (see below).
Analysis of apoptosis and the cell cycle by
flow cytometry revealed that JAK2 knockdown
induced apoptosis but did not inhibit prolifera-
tion (Figures S1E and S1F). Conversely,
JMJD2C and RANBP6 knockdown caused
a 10%–15% increase in G1 phase of the cell
cycle and an 10% decrease in S phase after
6 days but did not induce apoptosis (Figures
S1G and S1H, and data not shown). Hence,
JMJD2C, RANBP6 and JAK2 are differentially
required for the proliferation and survival of
PMBL and HL lines with the 9p24 amplicon but
are not essential genes in other DLBCL
subtypes.
Autocrine Activation of JAK2
JAK2 protein was highly expressed in PMBL
and HL lines with JAK2 amplification, and
JAK2 phosphorylation was detected exclusivelyin these cells (Figure 3A; Figure S3A). To test the requirement for
JAK2 kinase activity, we treated lymphoma lines with a selective
JAK2 inhibitor, TG101348 (Geron et al., 2008; Lasho et al., 2008;
Wernig et al., 2008). TG101348 reduced STAT6 phosphorylation
in PMBL and HL lines (Figure 3B), decreased viable cells in
a dose-dependent fashion (Figure 3C) and induced apoptosis
in the same PMBL and HL lines that were sensitive to JAK2
knockdown (Figure 3D). Like the JAK2 shRNA, TG101348 did
not block cell cycle progression (Figure S1H). Similar effects
on cell viability and STAT6 signaling were obtained with another
JAK2 inhibitor, AZD1480 (Hedvat et al., 2009) (Figures S3B
and S3C).
Cancer Cell
Cooperative Epigenetic Changes by OncogenesAntibody inhibition of IL-13 decreased STAT6 phosphorylation
in all five HL lines and in all three PMBL lines (Figure 3E). Interest-
ingly, anti-IL-13 also reduced the cell surface expression of the
IL-13 receptor a chain (IL13Ra) in both cell types as did treat-
ment with the JAK2 inhibitor TG101348 (Figure 3F; see also
Figure S3D), suggested that IL-13 secretion initiates a positive
feedback loop that enhances IL-13 receptor expression and
signaling in PMBL and HL cells. We generated two shRNAs
that knocked down IL13Ra expression, reduced downstream
signaling in PMBL cells, and were selectively toxic to PMBL
and HL cells (Figures 3G and 3H; see also Figures S3E and
S3F). We conclude that amplification and overexpression of
JAK2 cooperates with autocrine IL-13 signaling to promote the
survival of PMBL and HL cells.
We next used both the JAK2 shRNA and TG101348 to identify
genes regulated by JAK2 signaling in K1106 PMBL cells (Fig-
ure S3G). Remarkably, this JAK2-regulated gene signature ac-
counted for roughly one-sixth (55/341; 16%) of the genes that
were more highly expressed in primary PMBL tumors than in
GCB DLBCL tumors (Figure S3G, lanes 1 and 2), a highly signif-
icant overlap (p = 2.4 E-36). Most of these genes were more
highly expressed in PMBL cases with the 9p24 amplicon than
in cases with wild-type 9p24 (p = 0.017), indicating that this
genetic abnormality has a broad influence on the signaling
output of the JAK2 pathway (Figure 3I; see also Figure S3G,
lanes 3–6). Of note, PMBL cases with wild-type 9p24 copy
number still had higher expression of these JAK2-regulated
genes than did GCB DLBCLs (p = 8.0 E-7), indicating that
JAK2 signaling imparts a pervasive phenotype in a majority of
PMBL tumors that is augmented by the 9p24 amplicon. More-
over, a majority of these JAK2-regulated genes were also more
highly expressed in HL lines than in GCB DLBCL lines (Fig-
ure S3G, lanes 7 and 8), demonstrating that JAK2 signaling
significantly shapes the biology of HL as well.
Functional Cooperation between JAK2 and JMJD2C
Because both JAK2 and JMJD2C canmodify the genome epige-
netically, we focused our subsequent work on themechanism by
which these two amplicon genesmight jointly alter PMBL and HL
biology. Our interest in JAK2 and JMJD2Cwas further stimulated
by a tissue microarray analysis that demonstrated high expres-
sion of these proteins in 70% and 38% of PMBL biopsies,
respectively, but in significantly fewer biopsies of other DLBCL
subtypes (Figure S4).
We investigated whether JAK2 and JMJD2C might coopera-
tively sustain the survival and proliferation of PMBL and HL cells.
To test this, we infected a population of cells with vectors
expressing an shRNA targeting JMJD2C or a control shRNA
together with GFP, and treated the cells with various concentra-
tions of the JAK2 inhibitor TG101348. The equal exposure of
both shRNA-transduced and nontransduced cells to the JAK2
inhibitor allowed us to compare the effects of JAK2 inhibition in
the two populations and observe a cooperative effect of JAK2
inhibition and JMJD2C knockdown. Knockdown of JMJD2C
alone was toxic for the K1106 PMBL line and the UH-01 HL
line, but treatment with the JAK2 inhibitor increased the loss of
shJMJD2C-transduced cells in a dose-dependent manner. By
contrast, expression of a control shRNA did not alter the sensi-
tivity of lymphoma cells to TG101348 (Figure 4A). In these exper-Caniments in which JAK2 and JMJD2C were simultaneously
inhibited, the effect of JMJD2C knockdown was still restricted
to cell cycle blockade whereas JAK2 inhibition primarily induced
apoptosis (Figures S1G and S1H). Hence, the cooperative
toxicity of JAK2 and JMJD2C inactivation stems from their
dual inhibition of two primary oncogenic processes, proliferation
and survival. Of particular interest were the HL lines L540 and
KM-H2, in which JMJD2C knockdown alone was not toxic but
did sensitize the cells to the JAK2 inhibitor (Figure 4A). This result
suggests that JAK2 signaling and JMJD2C may affect the same
regulatory pathway in these cells in a partially redundant fashion.
The L428 HL line was not affected by combined inhibition of both
of these factors, indicating either that there is further functional
redundancy in this cell line for other amplicon genes (e.g.,
RANBP6) or that other survival pathways that are active in this
line play a dominant role, such as NF-kB (Emmerich et al.,
1999). The functional cooperation of the JAK2 inhibitor with
JMJD2C knockdown was not observed in the control GCB
DLBCL line SUDHL4 (Figure 4A).
To confirm the cooperation between JAK2 and JMJD2C, we
examined the effect of shRNA-mediated knockdown of these
two genes, either alone or in combination (Figure 4B). Cells
were first transduced with a vector expressing a JAK2 shRNA
or with an empty vector control and selected for stable retroviral
integration. These two cell populations were then transduced
with vectors expressing GFP together with a JMJD2C shRNA
or a control shRNA. We monitored the fraction of GFP+ cells
over time after shJMJD2C induction and compared the stable
pools expressing the JAK2 shRNA or the control shRNA. As
single agents, the JAK2 and JMJD2C shRNAs were toxic for
K1106 PMBL and L1236 HL cells but not for control GCB DLBCL
cells, as expected (Figure 4B). The toxicity of JMJD2C knock-
down was increased with dual knockdown of JAK2, confirming
the functional cooperation between these two factors. Also of
note, combined knockdown of JAK2 and JMJD2C was toxic to
L540 HL cells despite the fact that these cells were not sensitive
to knockdown of either gene alone, again suggesting that JAK2
and JMJD2C may redundantly regulate the same pathway in
these cells.
Activation of the MYC Transcriptional Network by JAK2
and JMJD2C
To investigate the molecular mechanisms of JAK2/JMJD2C
cooperation, we profiled gene expression in K1106 PMBL cells
after knockdown of these two genes.We identified a set of genes
that were downregulated both by JAK2 inhibition and by
JMJD2C inhibition, and compared this gene list to a database
of previously characterized gene expression signatures (Shaffer
et al., 2006). We observed a striking overlap between the genes
downmodulated by these treatments and signatures of MYC
target genes (Bild et al., 2006; Zeller et al., 2006) (Table S2A).
A signature of genes that are activated by MYC overexpression
(Bild et al., 2006) was downmodulated in expression when JAK2
or JMJD2C were inhibited (Figure 5A; see also Table S2B), as
was a set of genes that MYC directly binds and positively regu-
lates in B cells (Zeller et al., 2006) (Figure 5B; see also Figure S5).
In keeping with this observation, MYC mRNA and protein
expression levels were reduced after induction of these same
shRNAs and after JAK2 inhibition (Figure 5C). Interestingly,cer Cell 18, 590–605, December 14, 2010 ª2010 Elsevier Inc. 593
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Cancer Cell
Cooperative Epigenetic Changes by OncogenesMYC downregulation by the JAK2 inhibitor was dynamic, reach-
ing a nadir at 2 hr and partially recovering at later time points (Fig-
ure 5C), suggesting the possibility of homeostatic regulation of
MYC levels under these conditions. Of note, combined blockade
of JAK2 and JMJD2C reduced MYC protein levels more than
blockade of either regulator alone, in both K1106 PMBL cells
and in U-H01 HL cells (Figure 5D).
We next examined the dependence of PMBL and HL lines on
MYC using a previously validated shRNA targeting MYC (Shaffer
et al., 2008). Knockdown of MYC proved toxic to all lines except
for the myeloma U266, which expresses L-myc rather than
c-myc (encoded by MYC) (Figure 5E). Expression of the MYC
shRNA increased cell apoptosis but had little effect on cell prolif-
eration (Figures S1E and S1F). The toxic effect of the MYC
shRNA could be reversed by ectopic expression of a MYC
cDNA (Shaffer et al., 2008) and data not shown). We conclude
that MYC and its transcriptional network is an important aspect
of JAK2 and JMJD2C regulation that is required for the survival of
PMBL and HL cells. However, MYC is not the only important
downstream target of JAK2 and JMJD2C in these lymphomas
because MYC overexpression did not rescue PMBL cells from
the toxic effect of JAK2 or JMJD2C knockdown (data not
shown).
Cooperative Epigenetic Modulation by JAK2
and JMJD2C
JMJD2C is a demethylase for H3K9me3 (Cloos et al., 2006; Loh
et al., 2007; Wissmann et al., 2007), a histone mark that is recog-
nized by the chromo domain of HP1a (Bannister et al., 2001).
HP1a uses its chromo shadow domain to bind to a second
region on the histone H3 tail surrounding tyrosine 41, and phos-
phorylation of this residue by nuclear JAK2 prevents this interac-
tion (Dawson et al., 2009). Hence JMJD2C and JAK2 inhibit
HP1a recruitment and heterochromatin formation by distinct
mechanisms, suggesting the possibility that JAK2 and JMJD2C
might collaborate in modifying the epigenome of PMBL and HL
cells. On treatment of K1106 PMBL or U-H01 cells with the
JAK2 inhibitor TG101348, we observed a time-dependent
increase in total cellular H3K9me3 levels by immunoblotting,
suggesting that JAK2 signaling counteracts heterochromatin
formation in these lymphoma cells (Figure 6A).
To examine the cooperative effects of JAK2 inhibition and
JMJD2C knockdown, we treated K1106 and U-H01 cells with
low concentrations of the JAK2 inhibitor for a short period of
time (2 hr), with and without JMJD2C knockdown. At this time
point, the JAK2 inhibitor and the JMJD2C shRNA had little
impact on their own, but the JAK2 inhibitor clearly increased
H3K9me3 levels in cells in which JMJD2C had been silenced,Figure 2. Identification of shRNAs Selectively Toxic to PMBL and HL C
(A) Left panel: Schematic of the shRNA library screen to identify the genes on chrom
Each shRNA vector contains a unique barcode sequence that allows its abundan
lines transduced with the library, shRNAs can be induced by doxycycline (dox). T
code in shRNA-induced versus uninduced cells. See text and Experimental Proce
that were selectively toxic to PMBL and HL cells are displayed. Positive control sh
shRNA barcode depletion from the shRNA-induced culture, represent means ± s
(B) Validation of shRNA toxicity. Positive shRNAs (Figure 2A) were expressed usi
indicated in the top right panel. Live shRNA-expressing, GFP+ cells were monito
based on cells transduced with a negative control shRNA targeting luciferase. S
Candemonstrating their cooperative effect on chromatin structure
in these lymphoma cells (Figure 6B).
Because the JAK2 inhibitor TG101348 induces cell apoptosis,
we examined whether an increase in H3K9me3 is a general
feature of apoptosis.We induced apoptosis in K1106 PMBL cells
with the topoisomerase II inhibitor VP16, and chose a dose
(1.25 mM) that yielded apoptosis comparable to that achieved
with 2 mM TG101348 (Figure S6A). VP16-induced apoptosis
was not associated with any increase in H3K9me3 over a 24-hr
period. Because knockdown of JMJD2C blocks proliferation,
we additionally examined whether cell cycle inhibition generally
increased H3K9me3 levels. Treatment of K1106 PMBL cells
with a specific CDK inhibitor, PD0332991, caused proliferation
arrest but did not increase H3K9 trimethylation (Figure S6B).
We conclude that the rise in H3K9me3 associated with JAK2
and JMJD2C inhibition in PMBL and HL cells is not an indirect
consequence of either apoptosis or cell cycle blockade.
The influence of JAK2 and JMJD2C on H3K9 methylation
prompted us to study whether these factors globally alter
heterochromatin content in these lymphomas. HP1a is a marker
of heterochromatin that can be quantitatively assessed by
immunofluorescence (Dawson et al., 2009). Treatment with
the JAK2 inhibitor TG101348 or knockdown of JMJD2C
increased the number of HP1a foci per nucleus (Figures 6C
and 6D), and the intensity of the HP1a foci increased under
both conditions (Figures 6C and 6E). When JAK2 and JMJD2C
were simultaneously inhibited, the HP1a intensity increased
substantially, with a new population of high-intensity HP1a
foci clearly indicated by the shoulder on the HP1a intensity
histogram (Figure 6E). In cells expressing a control shRNA,
TG101348 did not produce this new population of high-intensity
HP1a foci (data not shown). We conclude that JAK2 and
JMJD2C cooperatively suppress heterochromatin formation in
PMBL cells.
The concerted effect of JAK2 and JMJD2C on MYC expres-
sion (Figure 5D) raised the possibility that the chromatin structure
of the MYC locus might be affected by these regulators. We
investigated H3K9me3 at theMYC locus by chromatin immuno-
precipitation (ChIP). Several pairs of primers for quantitative PCR
(QPCR) were designed to span most MYC regions required for
transcriptional regulation (Wierstra and Alves, 2008) (Figure 6F,
right panel). The JAK2 inhibitor TG101348 increased H3K9me3
localization to allMYC regions examined except intron 2, a region
without major transcriptional regulatory elements (Wierstra and
Alves, 2008), and these changes were echoed in cells in which
JAK2 was silenced by RNA interference (Figure 6F, upper and
middle left panels). The changes in H3K9me3 localization were
most pronounced in intron 1, where a minor transcription startells
osome band 9p24 essential for PMBL andHL cell proliferation and/or survival.
ce in a population of transduced cells to be measured by a microarray. In cell
he toxic effect of an shRNA is measured by the relative abundance of each bar
dures for details. Right panel: shRNAs targeting JMJD2C, RANBP6, and JAK2
RNAs are shown in the bottom panel. Data, expressed as log2-fold changes in
tandard deviation (SD) of four parallel infections.
ng a retroviral vector that coexpressed GFP and were screened for toxicity as
red by flow cytometry over time after shRNA induction. Data were normalized
ee also Figure S1 and Table S1.
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Figure 3. Active JAK2-STAT6 Required for Survival of PMBL and HL Cells
(A) Immunoblotting for total and phosphorylated JAK2 protein in the indicated lines. NS: nonspecific band.
(B) JAK2 kinase inhibition reduces STAT6 phosphorylation. Cells were treated with 2 mM TG101348 for 2 hr.
(C) Cell viability by MTT assay after 72 hr treatment of the indicated lines with TG101348.
(D) Flow cytometric analysis of apoptotic cells. The percentage of activated caspase 3-positive cells was calculated relative to cells treated with the dimethyl
sulfoxide (DMSO) carrier alone.
(E and F) The indicated lines were treated with anti-IL-13 antibody (20 mg/ml) or an isotype control antibody for 18 hr and analyzed by immunoblotting for total and
phosphorylated STAT6 (E) or by flow cytometry for IL13RA1 expression (F).
(G) Immunoblotting for the indicated proteins in K1106 cells expressing IL13RA1 shRNAs.
(H) Cell survival assay in the indicated lines expressing the IL13RA1-2 shRNA.
Cancer Cell
Cooperative Epigenetic Changes by Oncogenes
596 Cancer Cell 18, 590–605, December 14, 2010 ª2010 Elsevier Inc.
Days after shRNA induction 
shLuc control
Viable cells 
    shRNA + 
shRNA%
shRNA
induced
JAK2
inhibitor
_ _
_+
+
+
+
400 nM 
600 nM 
800 nM 
Cell lineshJMJD2C-3
 - 
K1106
(PMBL)
0 2 4 6 8 10 12 14 16 0 2 4 6 8 10 12 14 16
0
20
40
60
80
100
120
L540
(HL)
0
20
40
60
80
100
120
0 2 4 6 8 10 12 14 16 0 2 4 6 8 10 12 14 16
U-HO1
(HL)
0
20
40
60
80
100
120
0 2 4 6 8 10 12 14 16 0 2 4 6 8 10 12 14 16
KM-H2
(HL)
0
20
40
60
80
100
120
0 2 4 6 8 10 12 14 16 0 2 4 6 8 10 12 14 16
SUDHL4
(GCB
DLBCL)
0
20
40
60
80
100
120
0 2 4 6 8 10 12 14 16 0 2 4 6 8 10 12 14 16
0
20
40
60
80
100
120
0 2 4 6 8 10 12 14
0
20
40
60
80
100
120
0 2 4 6 8 10 12 14
0
20
40
60
80
100
120
0 2 4 6 8 10 12 14
0
20
40
60
80
100
120
0 2 4 6 8 10 12 14
Vector + shLuc-GFP control
Vector + shJAK2-GFP
Vector + shJMJD2C-GFP
shJAK2 + shJMJD2C-GFP
Viable cells
GFP
GFP%
 - 
+
K1106
(PMBL)
L540
(HL)
L1236
(HL)
SUDHL4
(GCB
DLBCL)
Days after shRNA induction 
A B Cell line
Figure 4. Cooperative Toxicity of JAK2 Inhibition and JMJD2C Knockdown
(A) The indicated lines were transduced with vectors expressing a JMJD2C shRNA or a control luciferase shRNA. Cells were treated with a range of concentra-
tions of TG101348 (red lines) or the DMSO carrier alone (blue lines) and simultaneously induced for shRNA expression using doxycycline. As controls (green lines),
cells were treated with the DMSO carrier and were not induced for shRNA expression. shRNA-expressing cells were monitored by flow cytometry for a coex-
pressed GFP marker, as described in Figure 2B. The ratio of live GFP-positive cells to GFP-negative cells for each time point was normalized to the day 0 value.
(B) Cooperative effect of shRNAs targeting JAK2 and JMJD2C. See text for details. See also Figure S4.
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Cooperative Epigenetic Changes by Oncogenessite (p3) resides just upstream of themajor translation start site of
MYC (Wierstra and Alves, 2008) (Figure 6F, right panel). Similar
increases in H3K9me3 localization at the MYC locus occurred
on JMJD2C knockdown (Figure 6F, lower left panel). Together,
these results suggest that JAK2 and JMJD2C inhibition cause
theMYC locus to adopt a repressive heterochromatic structure.
In keeping with this model, a marker of active chromatin, histone
H3 lysine 4 trimethylation, was diminished at the MYC locus by
treatment with the JAK2 inhibitor (Figure 6G). Moreover, JAK2
inhibition increased recruitment of the heterochromatin protein
HP1a to the MYC locus, as would be predicted by the increase(I) Left: Average expression of 55 JAK2-regulated genes that are highly expresse
gories. Right: Average JAK2 signature expression within each lymphoma categ
DLBCL. Error bars represent standard error of mean (SEM). See also Figure S3.
Canin H3K9me3, which is bound by HP1a (Figure 6H). Thus, MYC
adopts a repressive chromatin structure on silencing of JAK2
or JMJD2C, in keeping with its decreased expression under
these conditions.
Epigenetic Modulation by JAK2 Phosphorylation
of Histone H3 Tyrosine 41
Recent evidence suggests that JAK2 can modify the epigenome
in mammalian cells by phosphorylating tyrosine 41 of the histone
H3 tail (H3Y41p), thereby diminishing the recruitment of HP-1a
(Dawson et al., 2009). We localized H3Y41 phosphorylationd in PMBL (Figure S3G) in primary biopsies of the indicated lymphoma cate-
ory with p-values indicating significantly higher levels in PMBL than in GCB
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Figure 5. The MYC Target Gene Network Depends on JAK2 and JMJD2C in PMBL and HL
(A) Average expression levels of genes belonging to a set ofMYC targets (Bild et al., 2006) after knockdown of JAK2 or JMJD2C in K1106 PMBL cells, or treatment
with the JAK2 inhibitor TG101348 (2 mM). Expression is illustrated relative to cells without shRNA induction or relative to DMSO-treated cells, as indicated. Error
bars represent SEM.
(B) Relative expression levels of 401 direct MYC target genes (Zeller et al., 2006) in K1106 cells, as treated in Figure 5A, depicted according to the color scale
shown.
(C) MYC protein levels by immunoblotting and MYCmRNA levels by QPCR (normalized to b-2-microglobulin mRNA levels) in K1106 cells after JAK2 or JMJD2C
knockdown, or after treatment with 2 mM TG101348. mRNA data represent mean ± SD (n = 3).
(D) Cooperative downregulation of MYC protein by JAK2 and JMJD2C inhibition. K1106 PMBL or U-H01 HL cells were induced for expression of an shRNA tar-
geting JMJD2C for 2 days, or were uninduced. Cells were treated with the indicated concentrations of TG101348 for 2 hr and analyzed by immunoblotting as
indicated (left). Densitometric analysis of MYC protein levels relative to total histone H3 levels in the indicated samples (right).
(E) Knockdown of MYC is toxic to PMBL and HL lines. The U266 myeloma line, which expresses L-MYC but not c-MYC, served as a negative control. See also
Figure S5 and Table S2.
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Cooperative Epigenetic Changes by Oncogenesacross the genome by ChIP followed by high-throughput DNA
sequencing (ChIP-Seq), comparing K1106 PMBL cells treated
with the JAK2 inhibitor TG101348 with control cells treated
with the vehicle dimethyl sulfoxide (DMSO). Overall, we identified
9087 H3Y41 peaks in the combined data set, 65% of which were
in the vicinity of a protein-coding gene either within the body of
the gene (72%) or in the promoter region within 2 kb of the tran-
scriptional start site (28%). For 2140 genes, H3Y41p marks were
more prominent in the control cells than in cells treated with the
JAK2 inhibitor and consequently we will refer to these as JAK2
direct target genes (Table S3). As in leukemias with mutant
JAK2 isoforms (Dawson et al., 2009), LMO2 was a JAK2 direct
target gene in PMBL (Figure S7A). Among 341 genes that598 Cancer Cell 18, 590–605, December 14, 2010 ª2010 Elsevier Incwere more highly expressed in PMBL than GCB DLBCL
tumors, >20% (n = 75; 22%) were JAK2 direct target genes,
a highly significant overlap (p = 4.1E-22) (Figure S7B). These
genes include PDCD1L2 and CD274, which encode the T cell
inhibitory ligands PD-L2 and PD-L1 that are hallmarks of PMBL
(Rosenwald et al., 2003). Likewise, among 914 genes that were
downregulated on JAK2 inhibition in PMBL cells, nearly 25%
(n = 216; 23.6%) were JAK2 direct target genes, again highly
significant (p = 2.1E-71) (Figure S7C). By contrast, among 416
genes that were upregulated after JAK2 inhibitor treatment
(data not shown), <10% (n = 41; 9.8%) were JAK2 direct target
genes, little more than expected by chance. We conclude that
JAK2 modifies the chromatin surrounding a substantial subset.
Cancer Cell
Cooperative Epigenetic Changes by Oncogenes(8%) of all protein-coding genes in PMBL cells and that these
JAK2 direct targets are enriched for genes that are transcription-
ally activated by JAK2 signaling in these lymphomas.
The MYC locus had especially notable H3Y41p peaks that
were significantly diminished on JAK2 inhibitor treatment (p <
0.001) (Figure 7A). A prominent H3Y41p peak spanning the
MYC intron 1-exon 2 boundary overlapped the region that was
modified by H3K9me3 and HP-1a on JAK2 inhibition (Figure 6F);
JAK2-induced phosphorylation of this region was confirmed by
QPCR (Figure 7B). These observations support the notion that
dysregulated MYC expression in PMBL results from epigenetic
changes at the MYC locus initiated by JAK2 phosphorylation of
nucleosomes.
Also notable were H3Y41p peaks at both the JAK2 and
JMJD2C loci (Figures 7C and 7E), which were confirmed by
QPCR (Figure S7D). On treatment of K1106 PMBL cells with
the JAK2 inhibitor TG101348, JAK2 mRNA levels decreased,
suggesting that JAK2 signaling creates a feed-forward loop
that enhances its own expression (Figure 7D). Similarly,
TG101348 treatment or shRNA-mediated knockdown of JAK2
decreased JMJD2C mRNA levels (Figure 7F), revealing another
mechanism by which JAK2 and JMJD2C act cooperatively in
PMBL.
Another JAK2 direct target gene, IL4R, encodes the IL-4
receptor a chain (IL4Ra), which is an integral component of the
IL-13 receptor that increases its affinity for IL-13 by 2–3 orders
of magnitude (Andrews et al., 2002; LaPorte et al., 2008) (Fig-
ure 7G). H3Y41 phosphorylation of the IL4R locus was confirmed
byChIP (Figure S7D), and JAK2 inhibitor treatment of PMBL cells
decreased IL4RmRNA and protein levels (Figure 7H). These data
suggest that JAK2-mediated epigenetic modification creates
another positive autoregulatory loop that could augment the
autocrine IL-13 signaling that is characteristic of PMBL and HL
(Figures 3E–3H).
DISCUSSION
Cancer genome copy number changes are opportunistic, prefer-
entially altering chromosomal regions that provide the greatest
selective advantage for the malignant clone. This principle is
exemplified by a recurrent chromosome amplicon in PMBL
and HL that does not focus on a single gene but rather on
a several megabase region on chromosome band 9p24. Using
a functional genomics screen, we discovered that three ampli-
con genes—JAK2, JMJD2C, and RANBP6—are required for
the proliferation and survival of lymphoma lines bearing this am-
plicon. These genes are not essential to human cells in general
because lymphoma lines lacking this amplicon were not depen-
dent on these genes. It thus appears that amplification of this
genomic region creates a simultaneous addiction to these three
genes. In some lines, inactivation of any one of these genes was
toxic. In others, the simultaneous inactivation of JAK2 and
JMJD2C was required to efficiently kill the cells. Our results
thus demonstrate that a cancer amplicon can harbor more
than one ‘‘driver’’ gene, and suggest that functional genomics
will be required to gain a full understanding of the multiple addic-
tions created by amplicons. This understanding may in turn lead
to the rational combination of therapeutic agents targeting these
addictions.CanAlthough JAK2 is amplified in both PMBL and HL, mutations
such as those in myeloproliferative disorders have not been
found in these lymphoma types (Melzner et al., 2006; Wu et al.,
2009). Rather, our data suggest that wild-type JAK2 is activated
by autocrine IL-13 signaling in these lymphomas and that the
9p24 amplicon increases signal strength through this pathway.
STAT6 activation was blocked in all PMBL and HL lines treated
with an anti-IL-13 antibody, and IL13Ra knockdown had a similar
effect. IL-13 signaling in PMBL and HL cells upregulated expres-
sion of IL13Ra, thereby creating a positive feed-forward loop.
Perhaps as a result, expression of IL13RA1 mRNA is a hallmark
of PMBL and HL that distinguishes them from other lymphoma
types (Rosenwald et al., 2003; Savage et al., 2003). Moreover,
IL4R is a direct target of JAK2 histone phosphorylation in
PMBL, leading to increased expression of IL4Ra, a subunit of
the IL-13 receptor that significantly increases its affinity for IL-13.
Remarkably, one sixth of the genes that are characteristically
expressed in PMBL tumors relative to GCB DLBCL tumors were
activated by JAK2 signaling in a PMBL line. These JAK2-regu-
lated genes were more highly expressed in PMBL tumors even
in the absence of the 9p24 amplicon, suggesting that autocrine
IL-13 signaling and JAK2 activation takes place in the absence
of JAK2 amplification. However, the 9p24 amplicon further
increased expression of these JAK2-regulated genes suggesting
that one or more genes within the 9p24 amplicon augment the
signaling output of the JAK2 pathway. Thus, JAK2 signaling
has a defining influence on the biology of this lymphoma subtype
that is aided and abetted by the 9p24 amplicon.
The cooperation between JAK2 and the histone demethylase
JMJD2C suggests that JAK2 mediates its oncogenic effect in
PMBL and HL by modulating the epigenome. Classically, JAK
signaling mediates its biological effects by phosphorylating
STAT transcription factors that then transactivate target genes
bearing STAT binding motifs (Ghoreschi et al., 2009). This
signaling pathway undoubtedly plays a role in modulating the
gene expression profile of PMBL and HL cells. However, of the
genes that were most downmodulated in expression on JAK2
inhibition in PMBL (n = 1701) and HL (n = 1027), only 2.5%
contain canonical STAT6 binding sites in their regulatory regions
(data not shown). Thus, much of the biology of PMBL and HL
cells that is controlled by JAK2 is likely to come from other regu-
latory mechanisms. Studies in Drosophila (Shi et al., 2006, 2008)
and human leukemia (Dawson et al., 2009) have highlighted the
ability of JAK signaling to globally decrease heterochromatin
formation. In our study, JAK2 cooperated with the histone deme-
thylase JMJD2C in several assays, suggesting that epigenetic
modulation by JAK2 is a key aspect of its oncogenic action in
lymphomas bearing the 9p24 amplicon. Specifically, inhibition
of JAK2 and JMJD2C cooperatively killed PMBL and HL lines,
increased genome-wide histone H3K9me3 levels, and promoted
heterochromatin formation. Moreover, inhibition of JAK2 and
JMJD2C cooperated to repress MYC expression, which was
associated with remodeling of the MYC locus by two hallmarks
of heterochromatin, H3K9me3 and HP1a recruitment.
Heterochromatin has been conceptually subdivided into
stable ‘‘constitutive’’ heterochromatin and dynamic ‘‘facultative’’
heterochromatin (reviewed in Trojer and Reinberg [2007]). The
local epigenetic modification that we observed at theMYC locus
is most reminiscent of the facultative heterochromatin state,cer Cell 18, 590–605, December 14, 2010 ª2010 Elsevier Inc. 599
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Figure 6. JAK2 and JMJD2C Modulate the Epigenome of PMBL and HL
(A) The K1106 PMBL and U-H01 HL lines were treated with the 2 mM TG101348 for the indicated times before immunoblotting for H3K9me3 or total histone H3.
Relative protein levels were quantitated by densitometry.
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Cooperative Epigenetic Changes by Oncogenessuch as is mediated by the Rb protein, which represses the
S-phase gene cyclin E during G1 phase by recruiting a histone
H3K9 methyltransferase, leading to HP1 recruitment (Nielsen
et al., 2001). On the other hand, JAK2 and JMJD2C inhibition
was associated with a microscopically discernible increase in
HP1a-associated nuclear speckles. Previous work has shown
that the chromatin in these nuclear domains recruits HP1a by
possessing H3K9me3 marks and lacking H3Y41 phosphoryla-
tion (Dawson et al., 2009). These nuclear domainsmay represent
the formation of stable foci of constitutive heterochromatin or
alternatively may represent the reversible recruitment of genes
such as MYC to nuclear regions where gene silencing occurs.
Our working model of the epigenetic cooperation between
JAK2 and JMJD2C is shown in Figure 8. Both regulators control
recruitment of the heterochromatin protein HP1a to histone tails,
but by different mechanisms. HP1a uses its chromo domain to
bind histone H3K9me3 (Bannister et al., 2001; Lachner et al.,
2001), and demethylation of this residue by JMJD2C removes
this HP1a binding site (Cloos et al., 2006; Loh et al., 2007;Whets-
tine et al., 2006; Wissmann et al., 2007). HP1a uses its chromo
shadow domain to bind to a second region of the histone H3
tail centered around tyrosine 41, and phosphorylation of this
residue by nuclear JAK2 blocks this binding (Dawson et al.,
2009). Because the chromo domain and the chromo shadow
domain are linked in the same polypeptide, the simultaneous
interaction with these two regions of the histone H3 tail would
be expected to cooperatively increase HP1a binding avidity. Of
note, HP1a also interacts with SUV39H1 (Yamamoto and
Sonoda, 2003) and SETDB1 (Verschure et al., 2005), which are
H3K9 methylases. SUV39H1 methyltransferase activity is
required for the spreading of heterochromatin and the recruit-
ment of HP1a. On a nucleosome lacking H3K9 methylation
and H3Y41 phosphorylation, HP1a might initially bind through
its chromo shadow domain to the histone H3 tail near tyrosine
41, thereby recruiting SUV39H1/SETDB1 to methylate lysine
9 and facilitate HP1a binding through its chromo domain. The
9p24 amplicon appears to engage both JAK2 signaling and
JMJD2C to decrease HP1a deposition genome-wide, thereby
promoting an active chromatin configuration surrounding func-
tionally critical genes, such as MYC. JAK2-mediated H3Y41
phosphorylation sets up several positive feedback loops by tar-
geting JMJD2C and JAK2 itself, as well as IL4R, which encodes
IL4Ra, a subunit of the IL-13 receptor.
Our findings have several implications for the development of
new therapeutic modalities for PMBL and HL. Despite the fact
that current chemotherapy regimens for HL are quite effective,
they fail to cure20% of patients with advanced stage HL (Diehl(B) K1106 or U-H01 cells transduced with JMJD2C shRNAs (shJMJD2C-3 and sh
before treatment with the indicated concentrations of TG101348 for 2h. H3K9me
tated by densitometry. The experiment was repeated three times with similar res
(C) Representative images of HP1a staining in K1106 cells that were induced to
(D) The number of HP1a foci per nucleus was quantitated under the indicated co
(E) Histogramofmean fluorescence intensity data from a confocal imaging analysi
calculated by a two-tailed t test.
(F–H) ChIP analysis of the MYC locus after JMJD2C knockdown or JAK2 inhibiti
JMJD2C were induced in K1106 cells for 2 days, or cells were treated with 2 mM
The location of threeMYC transcriptional start sites (p1, p2, p3) and two translatio
first normalized to the input DNA signal. The signals in the shRNA-induced and T
duced and DMSO-treated samples, respectively. Error bars represent SEM (n =
Canet al., 2003) and 25%of patients with PMBL (Zinzani et al., 2009).
Moreover, PMBL and HL tumors in the mediastinum are often
irradiated, causing later sequelae such as coronary artery
disease. Inhibitors of JAK2 signaling are just entering the clinic
and are beginning to show activity in myelofibrosis associated
with activating JAK2 mutations (Santos et al., 2010). The JAK2
pathway is an attractive therapeutic target in PMBL and HL
based on the genetic and functional evidence in the present
study along with previous work implicating SOCS1 inactivation
in PMBL and HL (Melzner et al., 2005; Mestre et al., 2005; Mottok
et al., 2009; Weniger et al., 2006) and autocrine IL-13 signaling in
HL (Skinnider et al., 2001, 2002). Together, these considerations
support the further development of JAK2 inhibitors as potential
therapeutic agents in these lymphomas.
Because of the functional redundancy between JAK2 and
JMJD2C in some lymphomas with the 9p24 amplicon, it is likely
that successful therapy of some cases might require simulta-
neous inhibition of both enzymes. For example, some HL lines
(KM-H2 and L540) showed little or no response to JAK2 inhibi-
tion or JMJD2C inhibition as single interventions, but were killed
when JAK2 and JMJD2C were simultaneously inhibited.
JMJD2C is a potentially druggable enzyme that is an attractive
therapeutic target because of its involvement in PMBL and HL.
Moreover, JMJD2C is a potentially interesting target in other
cancers such as esophageal carcinoma, which can amplify
JMJD2C and depend on JMJD2C for proliferation (Cloos
et al., 2006; Yang et al., 2000), and prostate cancer, which
can rely on JMJD2C for androgen-dependent proliferation
(Wissmann et al., 2007). It is important to emphasize that
JMJD2C is not required by all cells for proliferation and survival,
potentially opening a therapeutic window for cancer treatment.
The development of JMJD2C-directed therapeutics may be
especially attractive in PMBL and HL as they may have cooper-
ative activity with JAK2-directed agents that are already in clin-
ical trials.EXPERIMENTAL PROCEDURES
Array Comparative Genomic Hybridization
Array comparative genomic hybridization (CGH) and gene-expression profiling
of DLBCL biopsies were described (Lenz et al., 2008). The National Cancer
Institute Institutional Review Board has approved the study and written
informed consent has been obtained.
Gene Expression
Gene expression profiling was performed using Agilent 4X44K whole genome
arrays (Shaffer et al., 2008). Quantitative RT-PCR was performed using
Applied Biosystems probes.JMJD2C-4) were induced for shRNA expression for 2 days, or left uninduced,
3 and total histone H3 levels were determined by immunoblotting and quanti-
ults.
express a JMJD2C shRNA, treated with TG101348, or both.
nditions. Data represent mean ± SEM.
s of HP1a nuclear foci in K1106 cells treated as indicated. ***p < 0.01; **p < 0.05,
on for H3K9me3 (F), H3K4me3 (G), and HP-1a (H). shRNAs targeting JAK2 or
TG101348 for 2 hr. Primers from the MYC locus are shown at the upper right.
n initiation codons (CTG, ATG) are shown. The median value of the signals was
G101348-treated samples were further normalized to those from shRNA-unin-
3). See also Figure S6.
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Figure 7. JAK2-Mediated Histone H3Y41 Phosphorylation in PMBL and HL
(A) H3Y41p at theMYC locus. Shown are H3Y41p ChIP-seq histograms in K1106 PMBL cells treated with 2 mM TG101348 for 4 hr or with DMSO as a negative
control.
(B) ChIP analysis of H3Y41p at theMYC locus with and without treatment with TG101348 (2 mM) for 4 hr. QPCR was performed using the indicated primers from
MYC and negative control primers from the ubiquitin B promoter. The median value of H3Y41p signals was normalized to the input DNA signal. Error bars repre-
sent SEM (n = 3).
(C) H3Y41p at the JAK2 locus, as in Figure 7A.
(D) QPCR analysis of JAK2 mRNA levels in K1106 cells treated with 2 mM TG101348 for the indicated times or with DMSO. Error bars represent SEM (n = 3).
(E) H3Y41p at the JMJD2C locus, as in Figure 7A.
(F) QPCR analysis of JMJD2C mRNA levels. K1106 cells were treated as in Figure 7D (left) or induced to express shJAK2-1 or a negative control shRNA for the
indicated days (right). Error bars represent SEM (n = 3).
(G) H3Y41p at the IL4R locus, as in Figure 7A.
(H) QPCR analysis of IL4RmRNA levels in K1106 cells, as treated in Figure 7D (left), and FACS analysis of the IL4Ra on the surface of K1106 cells after treatment
with 2 mM TG101348 for 18h or with DMSO (right). Error bars represent SEM (n = 3). See also Figure S7 and Table S3.
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Figure 8. Model of Cooperative Modulation of the Cancer Epigenome by JAK2 and JMJD2C
Autocrine signaling by IL-13 activates JAK2 kinase in PMBL and HL. Amplification of a genomic region on chromosome band 9p24 increases the abundance of
JAK2 and JMJD2C, both of which modify histone H3 tails and impede the recruitment of the heterochromatin protein HP1a. The active chromatin that results
facilitates the expression of genes such as MYC, JAK2, JMJD2C, and IL4R. See text for details.
Cancer Cell
Cooperative Epigenetic Changes by OncogenesThe JAK2 signaling signature (Figure 3I and Figure S3G) was defined as
those genes (n = 1035) that were decreased in abundance by 0.5 log2 in at
least two of four time points after knockdown of JAK2 and that were decreased
by 0.5 log2 in at least four of eight time points after treatment with TG101348.
Apoptosis Assays and Flow Cytometric Analysis
Apoptosis assays were performed by flow cytometric analysis of caspase 3
activity with a FITC-VAD-FMK kit (Promega). Cells grown in 96-well plates
were treated with TG101348 for 72 hr. FITC-VAD-FMK was added to the cells
(10 mM) for 20 min at 37C and cells were harvested and washed with PBS
before FACS.
ChIP-Seq for H3Y41 Phosphorylation
Chromatin immunoprecipitated with anti-H3Y41p antibody was used to
construct ChIP-Seq libraries (Illumina), selecting genomic fragments
350 bp in size. Single-end 36 bp sequence tags were obtained using libraries
from K1106 PMBL cells treated with 2 mMTG101348 or DMSO for 4 h. H3Y41p
peaks were defined for the combined data set and peaks with significantly
fewer sequence tags from the TG101348-treated data were identified.
See additional methods in the Supplemental Experimental Procedures.
ACCESSION NUMBERS
Array data have been deposited into the GEO database with accession
number GSE20988. Data of ChIP-seq for H3Y41 phosphorylation have been
deposited in the NCBI sequence archive with accession number SRP003320.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and three tables and can be found with this article online at
doi:10.1016/j.ccr.2010.11.013.CanACKNOWLEDGMENTS
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